Two medicines, side by side
Eravacycline vs omadacycline
Eravacycline has no indication this site maps; omadacycline has no indication this site maps. Their labels share no use, so they are not alternatives to each other. Drugs@FDA records approvals of eravacycline since 2018 and of omadacycline since 2018. How each works, in its label's words: Eravacycline, “Eravacycline is an antibacterial drug [see Microbiology ( 12.4 )].”; Omadacycline, “NUZYRA is an antibacterial drug [see Microbiology (12.4) ].”
Check it at the source: the eravacycline FDA label on DailyMed (effective March 31, 2025); the omadacycline FDA label on DailyMed (effective May 27, 2026).
Highlights of the eravacycline record
Eravacycline (Xerava) · label of March 31, 2025
Used for
From the label: indicationsXERAVA is a tetracycline class antibacterial indicated for the treatment of complicated intra‑abdominal infections in patients 18 years of age and older. ( 1.1 ) Limitations of Use XERAVA is not indicated for the treatment of complicated urinary tract infections (cUTI). […]
On the market
- Earliest approval on file
- August 27, 2018
- Generic labelers
- none listed
- Pharmacy cost
- Not in the survey
Supply and safety
- Shortage
- No current entry
- Recalls
- 0
Highlights of the omadacycline record
Omadacycline (Nuzyra) · label of May 27, 2026
Used for
From the label: indicationsNUZYRA is a tetracycline class antibacterial indicated for the treatment of adult patients with the following infections caused by susceptible microorganisms ( 1 ): Community-acquired bacterial pneumonia (CABP) ( 1.1 ) Acute bacterial skin and skin structure infections (ABSSSI) ( 1.2 ) To reduce the development of drug-resistant bacteria and maintain the effectiveness of NUZYRA and other antibacterial drugs, NUZYRA should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria. […]
On the market
- Earliest approval on file
- October 2, 2018
- Generic labelers
- none listed
- Pharmacy cost
- Not in the survey
Supply and safety
- Shortage
- No current entry
- Recalls
- 0
Source: FDA drug labels via openFDA (Eravacycline label of March 31, 2025, Omadacycline label of May 27, 2026); NDC Directory, Drugs@FDA, NADAC, FDA shortages and recalls (October 8, 2026)
How do eravacycline and omadacycline differ on the record?
How each works, in its label's words: Eravacycline, “Eravacycline is an antibacterial drug [see Microbiology ( 12.4 )].”; Omadacycline, “NUZYRA is an antibacterial drug [see Microbiology (12.4) ].”
Both are in FDA's class tetracycline-class antibacterials.
| Eravacycline | Omadacycline | |
|---|---|---|
| Labeled for | n/a | n/a |
| Pharmacologic class | Tetracycline-class Antibacterial | Tetracycline-class Antibacterial |
| How it works (label) | Eravacycline is an antibacterial drug [see Microbiology ( 12.4 )]. | NUZYRA is an antibacterial drug [see Microbiology (12.4) ]. |
| Half-life (label) | Elimination The mean elimination half-life is 20 hours. | n/a |
| Earliest approval on file (Drugs@FDA) | August 27, 2018 | October 2, 2018 |
| First generic approved | none | none |
| Generic labelers (NDC) | none listed | none listed |
| Pharmacy cost (NADAC, each one's most listed form; strengths differ) | n/a | n/a |
| 12-month price change | n/a | n/a |
| Boxed warning | No | No |
| Shortage now | No current entry | No current entry |
| Recalls recorded | 0 | 0 |
| FAERS reports (a report is not proof of cause; counts follow how widely a medicine is used) | 243 | 1,642 |
| DEA schedule | none | none |
Source: Drugs@FDA, FDA NDC Directory, CMS NADAC of October 7, 2026, FDA shortages and recalls, FAERS via openFDA (FDA files October 8, 2026)
What next?
- Alternatives to eravacycline
- every medicine labeled for the same conditions